JP2020535161A5 - - Google Patents

Download PDF

Info

Publication number
JP2020535161A5
JP2020535161A5 JP2020517388A JP2020517388A JP2020535161A5 JP 2020535161 A5 JP2020535161 A5 JP 2020535161A5 JP 2020517388 A JP2020517388 A JP 2020517388A JP 2020517388 A JP2020517388 A JP 2020517388A JP 2020535161 A5 JP2020535161 A5 JP 2020535161A5
Authority
JP
Japan
Prior art keywords
composition
patient
hypertension
fusion protein
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020517388A
Other languages
English (en)
Japanese (ja)
Other versions
JP7511469B2 (ja
JP2020535161A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/052795 external-priority patent/WO2019067502A1/en
Publication of JP2020535161A publication Critical patent/JP2020535161A/ja
Publication of JP2020535161A5 publication Critical patent/JP2020535161A5/ja
Priority to JP2023007311A priority Critical patent/JP7598960B2/ja
Application granted granted Critical
Publication of JP7511469B2 publication Critical patent/JP7511469B2/ja
Priority to JP2024209675A priority patent/JP2025023189A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020517388A 2017-09-27 2018-09-26 組換えエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ(npp1)を使用して心血管機能を改善し、心血管疾患を処置するための方法。 Active JP7511469B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023007311A JP7598960B2 (ja) 2017-09-27 2023-01-20 組換えエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ(npp1)を使用して心血管機能を改善し、心血管疾患を処置するための方法。
JP2024209675A JP2025023189A (ja) 2017-09-27 2024-12-02 組換えエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ(npp1)を使用して心血管機能を改善し、心血管疾患を処置するための方法。

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762563829P 2017-09-27 2017-09-27
US62/563,829 2017-09-27
PCT/US2018/052795 WO2019067502A1 (en) 2017-09-27 2018-09-26 METHODS FOR IMPROVING CARDIOVASCULAR FUNCTION AND TREATING CARDIOVASCULAR DISEASE USING RECOMBINANT ECTO-NUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023007311A Division JP7598960B2 (ja) 2017-09-27 2023-01-20 組換えエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ(npp1)を使用して心血管機能を改善し、心血管疾患を処置するための方法。

Publications (3)

Publication Number Publication Date
JP2020535161A JP2020535161A (ja) 2020-12-03
JP2020535161A5 true JP2020535161A5 (enExample) 2021-11-04
JP7511469B2 JP7511469B2 (ja) 2024-07-05

Family

ID=63858139

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020517388A Active JP7511469B2 (ja) 2017-09-27 2018-09-26 組換えエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ(npp1)を使用して心血管機能を改善し、心血管疾患を処置するための方法。
JP2023007311A Active JP7598960B2 (ja) 2017-09-27 2023-01-20 組換えエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ(npp1)を使用して心血管機能を改善し、心血管疾患を処置するための方法。
JP2024209675A Pending JP2025023189A (ja) 2017-09-27 2024-12-02 組換えエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ(npp1)を使用して心血管機能を改善し、心血管疾患を処置するための方法。

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023007311A Active JP7598960B2 (ja) 2017-09-27 2023-01-20 組換えエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ(npp1)を使用して心血管機能を改善し、心血管疾患を処置するための方法。
JP2024209675A Pending JP2025023189A (ja) 2017-09-27 2024-12-02 組換えエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ(npp1)を使用して心血管機能を改善し、心血管疾患を処置するための方法。

Country Status (5)

Country Link
US (2) US12134790B2 (enExample)
EP (1) EP3687565A1 (enExample)
JP (3) JP7511469B2 (enExample)
CA (1) CA3096821A1 (enExample)
WO (1) WO2019067502A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3471747A1 (en) 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
CA3180119A1 (en) * 2020-05-27 2021-12-02 Frank RUTSCH Compositions and methods for inhibiting vascular smooth muscle cell proliferation
KR20230048480A (ko) * 2020-05-27 2023-04-11 이노자임 파마, 인코포레이티드 말초 동맥 질환을 치료하기 위한 조성물 및 방법
EP4162036A1 (en) 2020-06-09 2023-04-12 Inozyme Pharma, Inc. Soluble enpp1 or enpp3 proteins and uses thereof
MX2024003506A (es) * 2021-09-24 2024-04-23 Inozyme Pharma Inc Formulaciones de polipéptidos enpp1 liofilizados y usos de estas.

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US20020164782A1 (en) 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
JPH04292169A (ja) 1991-03-19 1992-10-16 Sekisui Chem Co Ltd ハイブリッド型人工膵臓
US5418618A (en) 1992-03-09 1995-05-23 Mita Industrial Co., Ltd. Tone processing method for forming a halftone image
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5808656A (en) 1993-09-15 1998-09-15 Oce Printing Systems Gmbh Arrangement and process for generating a matrix image on a photosensitive recording substrate
WO1995019570A1 (en) 1994-01-14 1995-07-20 Genentech, Inc. Antagonists to insulin receptor tyrosine kinase inhibitor
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US6825396B2 (en) 1996-06-12 2004-11-30 Board Of Trustees Operating Michigan State University Methods for tissue specific synthesis of protein in eggs of transgenic hens
CA2280957A1 (en) 1997-02-14 1998-08-20 Leslie Orgel Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
EP1002119A1 (en) 1997-07-31 2000-05-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeted hsv vectors
US20040019923A1 (en) 1997-10-16 2004-01-29 Ivarie Robert D. Exogenous proteins expressed in avians and their eggs
US5932465A (en) 1997-10-16 1999-08-03 Icos Corporation Phosphodiesterase 8A
AU752946B2 (en) 1997-10-16 2002-10-03 Avigenics, Inc. Vectors comprising a magnum-specific promoter for avian transgenesis
PT1032662E (pt) 1997-11-07 2006-07-31 Trillium Therapeutics Inc Metodos e composicoes para imunomodulacao.
US6894022B1 (en) 1998-08-27 2005-05-17 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US6272859B1 (en) 1998-10-02 2001-08-14 Caterpillar Inc. Device for controlling a variable geometry turbocharger
US6043056A (en) 1998-11-06 2000-03-28 Incyte Pharmaceuticals, Inc. Cell surface glycoproteins
HK1044468A1 (zh) 1998-12-03 2002-10-25 海斯塔泰克有限责任公司 治療哮喘和炎症的小肽和方法
US6596535B1 (en) 1999-08-09 2003-07-22 Targeted Genetics Corporation Metabolically activated recombinant viral vectors and methods for the preparation and use
JP3983449B2 (ja) 1999-10-15 2007-09-26 株式会社リコー パルス幅変調回路、光書き込み装置及び画像形成装置
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
ATE447622T1 (de) 2000-02-23 2009-11-15 Pxe Internat Inc Methoden und zusammensetzungen zur diagnose und behandlung von pseudoxanthoma elasticum und ähnlichen zuständen
JP2001274989A (ja) 2000-03-27 2001-10-05 Ricoh Co Ltd 画像処理装置及び画像処理方法並びにプリンタ出力装置
DE20121960U1 (de) 2000-04-06 2004-01-15 Epigenomics Ag Nukleinsäuren für die Diagnose von mit Metastase assoziierten Krankheiten
US20040030167A1 (en) 2000-08-08 2004-02-12 Hiroaki Takayama 3-Methyl-20-epi-vitamin d derivatives
US6521645B2 (en) 2000-11-20 2003-02-18 The University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20020108132A1 (en) 2001-02-02 2002-08-08 Avigenics Inc. Production of a monoclonal antibody by a transgenic chicken
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
WO2002092020A2 (en) 2001-03-23 2002-11-21 The Burnham Institute Compositions and methods for modulating bone mineral deposition
US7888372B2 (en) 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
AU2002324700A1 (en) 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
WO2003025146A2 (en) 2001-09-18 2003-03-27 Avigenics, Inc. Production of a transgenic avian by cytoplasmic injection
EP1537140B1 (en) 2001-11-07 2013-01-02 Agensys, Inc. Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
US7335761B2 (en) 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US7294507B2 (en) 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
WO2003072593A2 (en) 2002-02-21 2003-09-04 University Of Virginia Patent Foundation Bone targeting peptides
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
US20040071705A1 (en) 2002-06-21 2004-04-15 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
US20050090001A1 (en) 2003-10-07 2005-04-28 Parker Stephen H. Cell lines and methods for producing proteins
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
PL1759001T3 (pl) 2004-04-21 2011-09-30 Alexion Pharma Inc Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości
US9055984B2 (en) 2004-04-21 2015-06-16 DePuy Synthes Products, Inc. Sternal reconstruction system
US20050287284A1 (en) 2004-06-28 2005-12-29 Shukla Triveni P Processed meats comprising dietary fiber gel
US20090142347A1 (en) 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
WO2006050211A2 (en) 2004-10-28 2006-05-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
EP1813671A4 (en) 2004-11-19 2008-06-11 Ono Pharmaceutical Co SOLUBLE PROTEIN AND USE THEREOF
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
JP4495210B2 (ja) 2005-06-09 2010-06-30 パナソニック株式会社 振幅誤差補償装置及び直交度誤差補償装置
CA2610159C (en) 2005-06-10 2015-03-31 Altus Pharmaceuticals Inc. Methods to reduce oxalate concentration by administration of oxalate oxidase crystals
EP1736553A1 (en) 2005-06-17 2006-12-27 Centre National De La Recherche Scientifique ENPP1 (PC-1) gene haplotype associated with the risk of obesity and type 2 diabetes and their applications
US20090180989A1 (en) 2005-10-05 2009-07-16 Synageva Biopharma Corp. Compositions and methods for delivering nucleotide sequences to vertebrates
US11039942B2 (en) 2006-06-13 2021-06-22 Sino Medical Sciences Technology Inc. Drug eluting stent and method of use of the same for enabling restoration of functional endothelial cell layers
PT2046373E (pt) 2006-08-02 2013-05-06 Althea Technologies Inc Oxalato descarboxilase cristalizada e métodos de utilização
US20100113339A1 (en) 2006-09-08 2010-05-06 Ablynx N. V. Serum albumin binding proteins with long half-lives
WO2008065225A2 (es) 2006-11-28 2008-06-05 Proyecto De Biomedicina Cima, S.L. Vector viral y sus aplicaciones
US20080273206A1 (en) 2007-04-23 2008-11-06 University Of South Carolina Biomimetic Mineralization Method and System
DK2662448T3 (en) 2007-05-11 2017-03-20 Alexion Pharma Inc Bone-targeted alkaline phosphatase, kits and methods for its use
EP2178556B1 (en) 2007-06-18 2011-08-17 Oregon Health & Science University Protein c for use in maintaining hemostasis
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
AR071885A1 (es) 2008-05-23 2010-07-21 Wyeth Corp Proteinas de union al receptor de interleuquina 21
JP4888439B2 (ja) 2008-05-30 2012-02-29 ブラザー工業株式会社 画像読取装置および原稿サイズ決定プログラム
WO2011097456A2 (en) 2010-02-05 2011-08-11 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
EP2545080B1 (en) 2010-03-12 2017-05-10 Alexion Pharmaceuticals, Inc. Npp1 fusion proteins
EP2683742B1 (en) 2011-03-11 2018-12-19 Alexion Pharmaceuticals, Inc. Npp1 fusion proteins
WO2012130567A1 (en) 2011-03-29 2012-10-04 Beta-Cell Nv Method for encapsulated therapeutic products and uses thereof
WO2013074615A1 (en) 2011-11-14 2013-05-23 Yale University Compositions and methods for modulating coagulation
AU2014204045B2 (en) 2013-01-04 2018-10-18 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
PL2956163T3 (pl) 2013-02-13 2025-04-14 Yale University Kompozycje do leczenia patologicznego zwapnienia i kostnienia
WO2014152940A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
CN114717206A (zh) 2013-03-15 2022-07-08 Atyr 医药公司 组氨酰-trna合成酶-fc缀合物
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
CA2920856C (en) 2013-08-09 2026-03-03 Ardelyx, Inc. Ph modulating compounds for inhibiting gastrointestinal phosphate uptake
CA2924259C (en) 2013-09-19 2021-12-21 Universitatsspital Basel Artificial vascular graft
AU2015219339B2 (en) 2014-02-19 2020-03-05 Bioasis Technologies Inc. P97-IDS fusion proteins
GB2526339A (en) 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
US10973931B2 (en) 2014-09-16 2021-04-13 Universitat Autònoma De Barcelona Adeno-associated viral vectors for the gene therapy of metabolic diseases
HK1245662A1 (zh) 2014-12-19 2018-08-31 Alexion Pharmaceuticals, Inc. 治疗组织钙化的方法
US10926006B2 (en) 2015-02-26 2021-02-23 Remodeless Cv Ltd Drug eluting stent
EP3298140B1 (en) 2015-05-19 2024-04-24 Yale University Compositions for treating pathological calcification conditions, and methods using same
TN2018000163A1 (en) 2015-11-12 2019-10-04 Res Inst Nationwide Childrens Hospital Methods of treating muscular dystrophy
EP3377105A4 (en) * 2015-11-20 2019-04-24 Yale University COMPOSITIONS FOR THE TREATMENT OF ECTOPIC CALIBRATION DISORDERS AND METHODS THEREWITH
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
EP3471747A1 (en) * 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
US11390859B2 (en) 2016-08-05 2022-07-19 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
IL268198B2 (en) 2017-02-27 2024-10-01 Shattuck Labs Inc Tigit- and light-based chimeric proteins
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
JP2021523139A (ja) 2018-05-08 2021-09-02 イエール ユニバーシティ 腎石症の進行を遅らせるための組成物および方法

Similar Documents

Publication Publication Date Title
Ibraheem et al. Administration strategies for proteins and peptides
JP7304629B2 (ja) 突然変異rasペプチド及び化学療法剤を含むペプチドワクチン
RU2627451C2 (ru) Противовоспалительные композиции
RU2684398C2 (ru) Состав с постоянным соотношением инсулина гларгина/ликсизенатида
JP2016516016A5 (enExample)
CN105566497A (zh) 融合铁蛋白在疫苗和其他方面的应用
WO2007097251A1 (ja) 抗アミロイドβペプチド抗体産生誘導用のペプチドワクチン
JP2022533968A5 (enExample)
McCrystal et al. Phase I study of the cytotoxic agent N-[2-(dimethylamino) ethyl] acridine-4-carboxamide
JP2023033610A (ja) 組換えエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ(npp1)を使用して心血管機能を改善し、心血管疾患を処置するための方法。
JP2024523559A5 (enExample)
EP4520394A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
JPH06157343A (ja) ある種の疾病の予防および治療用医薬を製造するためのカリクレインインヒビターの使用
JP2017500316A5 (enExample)
JP2024531314A5 (enExample)
JP2014519514A5 (enExample)
CN119894507A (zh) 嵌合抗原受体(car)t细胞辅助疗法
CN115463118A (zh) 和厚朴酚在制备治疗或预防毛细血管瘤的药物中的用途
JP2003514622A (ja) 患者中のサイトカインインヒビターを除去するための方法およびシステム
JP2023544409A5 (enExample)
CN114129711B (zh) 度拉糖肽在制备抗肿瘤药物中的应用
Jha et al. Immunotherapy's Promising Potential for Cancer Treatment: Oncology-Immunotherapy for Cancer
JP2021518392A5 (enExample)
JP7168228B2 (ja) 脳神経疾患に対するペプチドワクチン及びペプチドワクチン組成物
CN110841069A (zh) 一种含有沙利度胺与抗真菌药物的药物组合物及应用